Last reviewed · How we verify
ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study (STOPDAPT-2)
The purpose of this study is to evaluate the safety of reducing dual antiplatelet therapy (DAPT) duration to 1 month after implantation of the everolimus-eluting cobalt-chromium stent (CoCr-EES).
Details
| Lead sponsor | Kyoto University, Graduate School of Medicine |
|---|---|
| Phase | Phase 4 |
| Status | COMPLETED |
| Enrolment | 3045 |
| Start date | 2015-12 |
| Completion | 2023-12-31 |
Conditions
- Coronary Artery Disease
Interventions
- 1-month DAPT
- 12-month DAPT
Primary outcomes
- Composite event of cardiovascular death/myocardial infarction/definite stent thrombosis/stroke/bleeding — 12-month
Composite event of cardiovascular death/myocardial infarction/definite stent thrombosis/stroke/bleeding defined as major or minor under the definition of Thrombolysis in Myocardial Infarction (TIMI) Study group
Countries
Japan